What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Enzyme
- Gene
Takenobu Kamada focuses on Internal medicine, Cardiology, Ischemia, Hepatitis C virus and Pathology.
His studies deal with areas such as Gastroenterology and Endocrinology as well as Internal medicine.
His Cardiology research incorporates themes from Doppler echocardiography, Surgery, Vascular disease and Ultrasound.
His Ischemia study combines topics from a wide range of disciplines, such as Anesthesia, Hippocampus, Blood flow and Programmed cell death.
His Hepatitis C virus research integrates issues from Chronic liver disease, Titer and Hepatitis C.
His research in Pathology intersects with topics in Neuroscience and Blood volume.
His most cited work include:
- 'Ischemic tolerance' phenomenon found in the brain (1002 citations)
- Vagally mediated heart rate recovery after exercise is accelerated in athletes but blunted in patients with chronic heart failure (790 citations)
- Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. (576 citations)
What are the main themes of his work throughout his whole career to date?
Takenobu Kamada mostly deals with Internal medicine, Cardiology, Endocrinology, Ischemia and Pathology.
His study on Internal medicine is mostly dedicated to connecting different topics, such as Gastroenterology.
He studies Stomach which is a part of Gastroenterology.
His Cardiology study frequently draws connections to adjacent fields such as Diastole.
His works in Diabetes mellitus and Insulin are all subjects of inquiry into Endocrinology.
Takenobu Kamada interconnects Anesthesia, Adenosine and Pharmacology in the investigation of issues within Ischemia.
He most often published in these fields:
- Internal medicine (55.34%)
- Cardiology (24.09%)
- Endocrinology (20.68%)
What were the highlights of his more recent work (between 1994-2011)?
- Internal medicine (55.34%)
- Cardiology (24.09%)
- Endocrinology (20.68%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Internal medicine, Cardiology, Endocrinology, Immunology and Gastroenterology.
His Internal medicine research focuses on Diabetes mellitus and how it relates to Insulin.
His research links Diastole with Cardiology.
He combines subjects such as Cotransporter, Cell culture and Molecular biology with his study of Endocrinology.
He has researched Hepatitis C virus in several fields, including Viral disease, Hepatocellular carcinoma and Hepatitis C.
The various areas that Takenobu Kamada examines in his Ischemia study include Anesthesia and Adenosine.
Between 1994 and 2011, his most popular works were:
- Glycation-dependent, reactive oxygen species-mediated suppression of the insulin gene promoter activity in HIT cells. (278 citations)
- The human glucokinase gene beta-cell-type promoter: an essential role of insulin promoter factor 1/PDX-1 in its activation in HIT-T15 cells. (208 citations)
- Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma (207 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Enzyme
- Gene
His primary scientific interests are in Internal medicine, Endocrinology, Cardiology, Immunology and Hepatitis C virus.
In his research on the topic of Internal medicine, Pathology and Hepatocellular carcinoma is strongly related with Gastroenterology.
His study explores the link between Endocrinology and topics such as Symporter that cross with problems in Tonicity, Macula densa and Medulla.
Takenobu Kamada has included themes like Vascular disease and Diastole in his Cardiology study.
His work in Hepatitis C virus addresses issues such as Interferon alfa, which are connected to fields such as Chemotherapy and Hepatitis C.
His studies in Ischemia integrate themes in fields like Hippocampus and Contractility.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
